The Determine HIV-1/2 Ag/Ab Combo test from Alere, Waltham, Mass, is the first FDA-approved rapid point-of-care test that detects both HIV-1/2 antibodies and the HIV-1 p24 antigen, which can appear 12 to 26 days after infection and prior to HIV-1/2 antibodies, which typically appear 20 to 45 days after infection. By permitting individuals to learn of their HIV status earlier, the test may reduce transmission and allow patients to begin treatment earlier. It simultaneously identifies free HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Alere Determine HIV 1/2 Ag/Ab Combo is currently available to all health facilities and laboratories that are licensed to conduct tests of moderate complexity under the CLIA program. For more information, visit Alere.